Evidence map›Paper›PMID 40662973›Full record

ArticleRadiology2025

Cancer Detection in Breast MRI Screening via Explainable AI Anomaly Detection.

Felipe Oviedo, Anum S Kazerouni, Philipp Liznerski, Yixi Xu, Michael Hirano, Robert A Vandermeulen, Marius Kloft, Elyse Blum, Adam M Alessio, Christopher I Li and 5 more

Abstract read
In one paragraph

Article in Radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Felipe OviedoAI for Good Lab, Microsoft, 1 Microsoft Way, 4330 150th Ave NE, Redmond, WA 98052.ORCID 0000-0001-9480-6539
Anum S KazerouniDepartment of Radiology, University of Washington School of Medicine, Seattle, Wash.ORCID 0000-0002-4200-534X
Philipp LiznerskiUniversity of Kaiserslautern-Landau, Kaiserslautern, Germany.ORCID 0009-0000-9067-8672
Yixi XuAI for Good Lab, Microsoft, 1 Microsoft Way, 4330 150th Ave NE, Redmond, WA 98052.
Michael HiranoDepartment of Radiology, University of Washington School of Medicine, Seattle, Wash.ORCID 0009-0009-6628-6076
Robert A VandermeulenBerlin Institute for the Foundations of Learning and Data, Berlin, Germany.
Marius KloftUniversity of Kaiserslautern-Landau, Kaiserslautern, Germany.ORCID 0000-0001-6829-3725
Elyse BlumDepartment of Radiology, University of Washington School of Medicine, Seattle, Wash.
Adam M AlessioDepartment of Biomedical Engineering, Michigan State University, East Lansing, Mich.ORCID 0000-0003-3371-8580
Christopher I LiFred Hutchinson Cancer Center, Seattle, Wash.ORCID 0000-0003-1543-0743
William B WeeksAI for Good Lab, Microsoft, 1 Microsoft Way, 4330 150th Ave NE, Redmond, WA 98052.ORCID 0000-0002-9918-1360
Rahul DodhiaAI for Good Lab, Microsoft, 1 Microsoft Way, 4330 150th Ave NE, Redmond, WA 98052.ORCID 0000-0003-3812-3906
Juan M Lavista FerresAI for Good Lab, Microsoft, 1 Microsoft Way, 4330 150th Ave NE, Redmond, WA 98052.
Habib RahbarDepartment of Radiology, University of Washington School of Medicine, Seattle, Wash.ORCID 0000-0003-4835-1478
Savannah C PartridgeDepartment of Radiology, University of Washington School of Medicine, Seattle, Wash.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Fred Hutchinson Breast Cancer Clinical Validation CenterU01CA152637 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Christopher I Li, Savannah Corrina Partridge · 2010 to 2026
$14.6M
Quantitative characterization of tumor heterogeneity using habitat imaging for the prediction of patient outcome in triple negative breast cancerK99CA293004 · NCI · UNIVERSITY OF WASHINGTON · PI KAZEROUNI, ANUM SYED · 2024 to 2025
$203k
NCI NIH HHS K99 CA293004NCI NIH HHS P30 CA015704NCI NIH HHS U01 CA152637
6 · The paper itself

Abstract

Background Artificial intelligence (AI) models hold potential to increase the accuracy and efficiency of breast MRI screening; however, existing models have not been rigorously evaluated in populations with low cancer prevalence and lack interpretability, both of which are essential for clinical adoption. Purpose To develop an explainable AI model for cancer detection at breast MRI that is effective in both high- and low-cancer-prevalence settings. Materials and Methods This retrospective study included 9738 breast MRI examinations from a single institution (2005-2022), with external testing in a publicly available multicenter dataset (221 examinations). In total, 9567 consecutive examinations were used to develop an explainable fully convolutional data description (FCDD) anomaly detection model to detect malignancies on contrast-enhanced MRI scans. Performance was evaluated in three cohorts: grouped cross-validation (for both balanced [20.0% malignant] and imbalanced [1.85% malignant] detection tasks), an internal independent test set (171 examinations), and an external dataset. Explainability was assessed through pixelwise comparisons with reference-standard malignancy annotations. Statistical significance was assessed using the Wilcoxon signed rank test. Results FCDD outperformed the benchmark binary cross-entropy (BCE) model in cross-validation for both balanced (mean area under the receiver operating characteristic curve [AUC] = 0.84 ± 0.01 [SD] vs 0.81 ± 0.01;

Indexed as

Artificial IntelligenceBreast NeoplasmsImage Interpretation, Computer-AssistedMagnetic Resonance ImagingAdultAgedBreastEarly Detection of CancerFemaleHumansMiddle AgedRetrospective StudiesSensitivity and Specificity

Identifiers

PMID40662973
PMCPMC12314762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.